---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-23-000034"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2023-10-13T23:59:59+00:00"
generated_at: "2026-06-10T00:04:50.446602+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# AbCellera takes ownership of anti-OX40L antibody from EQRx for autoimmune therapy

## Summary
- Acquired rights to an antibody drug candidate targeting Ox40 ligand from EQRx collaboration.
- Candidate is being developed for atopic dermatitis and other autoimmune/inflammatory indications.
- AbCellera is advancing the candidate into IND-enabling studies; updates to follow.
- No financial terms of the asset transfer were disclosed.

## SEC filing metadata
- accession: 0001703057-23-000034
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2023-10-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305723000034/0001703057-23-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305723000034/abcl-20230918.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-23-000034
- JSON: https://secwatch.observer/filing/0001703057-23-000034.json
- Plain text: https://secwatch.observer/filing/0001703057-23-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.